Feasibility RCT: In-MINDD Profiler & Supportive Environment

  • Research type

    Research Study

  • Full title

    Innovative Midlife Intervention for Dementia Deterrence (In-MINDD) feasibility randomised controlled trial in four European primary care settings

  • IRAS ID

    141644

  • Contact name

    Catherine O'Donnell

  • Contact email

    kate.odonnell@glasgow.ac.uk

  • Sponsor organisation

    NHS Greater Glasgow and Clyde, Research and Devel Central Office

  • ISRCTN Number

    ISRCTN98553005

  • Clinicaltrials.gov Identifier

    European Union Framework Seven Programme, 304979

  • Research summary

    In-MINDD stands for Innovative Midlife Intervention for Dementia Deterrence, a study seeking to understand if you can identify and support patients in mid-life change health behaviours which may be putting them at risk of developing dementia in later life. The overall project is trying to (i) develop a dementia risk model using modifiable risk factors, including physical and mental activity, BMI, cholesterol and blood pressure; (ii) implement this risk model by designing and supporting an on-line user environment; and (iii) test the feasibility and effectiveness of this through a primary care-based feasibility randomised controlled trial.

    This application relates to point (iii). We will do this by carrying out a randomised controlled trial, where we will randomly allocate a group of patients aged 40-60 to receive information on their dementia risk score and a personalised strategy to improve their lifestyle for a healthy brain (LIBRA). To support this, they will be able to access the In-MINDD on-line support site. Those in the control arm will receive care as usual. We will follow these patients for 6 months, before working out their risk score again. We will compare that score with the control group. At the end of the trial, we will give the control group their risk score, lifestyle advice and access to the on-line information.

    Because we are interested in whether this system works or not and what patients and health care professionals think of it, we will monitor patients use of the system. We will also interview patients and practitioners during the trial to see what they think of receiving such information and whether they act on it. Finally, we will analyse the data to see if there are any changes in dementia risk score, or in any individual health behaviour, between the intervention group and the control group.

  • REC name

    West of Scotland REC 5

  • REC reference

    14/WS/1039

  • Date of REC Opinion

    3 Jul 2014

  • REC opinion

    Favourable Opinion